Abstract Introduction Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor
tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this …

Data discrepancy between preclinical and clinical datasets poses a major challenge for
accurate drug response prediction based on gene expression data. Different methods of …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …

The past few years have witnessed a rapid shift in the treatments for patients with squamous
cell lung cancers (SQCLCs) after the US Food and Drug Administration approval of a …

Background Major guidelines do not recommend routine molecular profiling of lung
squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is …

Recent advances in Pharmacogenomics have made it possible to understand the reasons
behind the different response of a drug. Discovery of genetic variants and its association …

Objectives Potentially targetable genomic alterations have been identified in lung squamous
cell carcinoma (LUSC), but none have yet translated into effective therapy. We examined …

Personalized patient-precise medicine is being gradually incorporated into clinical practice
for the treatment of non-small-cell lung cancer (NSCLC). The EGFR pathway has been …

Introduction: Unlike lung adenocarcinoma patients, there is no FDA-approved targeted-
therapy likely to benefit lung squamous cell carcinoma patients. Materials and Methods: We …

Background LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …